AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
Log in

NASDAQ:GLYCGlycoMimetics Stock Price, Forecast & News

$3.76
-0.07 (-1.83 %)
(As of 07/2/2020 03:28 PM ET)
Add
Compare
Today's Range
$3.59
Now: $3.76
$3.81
50-Day Range
$2.83
MA: $3.05
$3.76
52-Week Range
$1.82
Now: $3.76
$13.44
Volume21,263 shs
Average Volume1.46 million shs
Market Capitalization$163.86 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Read More
GlycoMimetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.56 per share

Profitability

Net Income$-57,890,000.00

Miscellaneous

Employees50
Market Cap$163.86 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

How has GlycoMimetics' stock been impacted by COVID-19 (Coronavirus)?

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GLYC stock has increased by 27.9% and is now trading at $3.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GlycoMimetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GlycoMimetics.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for GlycoMimetics.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) announced its earnings results on Friday, May, 1st. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.12. The biotechnology company had revenue of $9 million for the quarter. View GlycoMimetics' earnings history.

What price target have analysts set for GLYC?

6 brokerages have issued 12 month price targets for GlycoMimetics' stock. Their forecasts range from $5.00 to $16.00. On average, they expect GlycoMimetics' share price to reach $8.75 in the next twelve months. This suggests a possible upside of 132.7% from the stock's current price. View analysts' price targets for GlycoMimetics.

Has GlycoMimetics been receiving favorable news coverage?

News headlines about GLYC stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. GlycoMimetics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about GlycoMimetics.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the following people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 60)
  • Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
  • Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
  • Mr. Henry Flanner, VP of Technical Operations

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $3.76.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $163.86 million. The biotechnology company earns $-57,890,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is www.glycomimetics.com.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.